Curis, Inc. (CRIS) Buy Target $1.79 Sell Target $2.10

Trade Setup

Buy Target $1.79
Sell Target $2.10

Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include CUDC-907, an oral dual inhibitor of HDAC and PI3K enzymes for the treatment of patients with MYC-altered diffuse large B-cell lymphoma and solid tumors; CA-170, an oral small molecule drug candidate for treating patients with advanced solid tumors and lymphomas; CA-4948, an oral small molecule drug candidate, which is in Phase I clinical trial for the treatment of non-hodgkin lymphomas; and CA-327, a pre-investigational new drug stage oncology drug candidate.


© Copyright 2020 Investing is Inherently Risky - There are risks inherent in all investments, which may make such investments unsuitable for certain persons. These include, for example, economic, political, currency exchange, rate fluctuations, and limited availability of information on international securities. You may lose all of your money trading and investing. Do NOT enter any trade without fully understanding the worst-case scenarios of that trade. And do NOT trade with money you cannot afford to lose. Past performance of an investment is not necessarily indicative of its future results. No assurance can be given that any implied recommendation will be profitable or will not be subject to losses.